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PROLOGUE 
Monday, February 9, 2004.  
 
To Mom and Dad 
 
It is cold outside. I am lying in bed trying to study, but the sleepiness after several 
days of high fever from having the flu, and the severe pain in my mouth from last 
week’s dental surgery is hampering my willingness. I am picking up the book, and 
while attempting to read, the phone starts ringing. I answer, but have barely time 
finishing my name, before Mom is interrupting, telling me about how hard it is getting 
in touch with me now that I am not living in their house anymore. As I am listening, I 
am recognizing that something is different in her voice that is drawing my attention. 
Why does it sounds as if she is swallowing? Is she sad? Why is she sad? Is it 
because I have moved? She is telling me that I should have come visiting them next 
week instead, that I should not be coming when I am having the flue and that I had 
infected Dad. I answer her that I did not know that I was going to have the flu, but 
she is not listening to me, saying that Dad also have had the flu, and he has been 
sick all week, repeating that I shouldn‘t be coming when I might have the flu and that 
he should not been infected. I could not understand why Mom was sounding so 
upset, after all, it was just the flu. I started thinking about the fact that Mom might be 
upset since I recently moved away from their home, that she is coping with her and 
Dad’s new life, and maybe Dad was sad for me having moved out.  
 
All of a sudden, she is quiet. I hear that she is taking a deep breath. She tells me that 
she needs me to sit down, because she is going to tell me something important and 
does not want me to fall down. What is she saying? I am not capable of replying. Her 
different voice and talk is making me anxious and my whole body becomes tense. 
This is not good, is all I am thinking. She is quiet, probably trying to gain momentum, 
but then she is starts talking. Dad has been out shoveling snow last night, although 
she had kept telling him not to. She had been promising him to do it herself in the 
morning the next day before going to work, saying that she really wanted him staying 
in bed since he needed to rest after several days of fever. Dad had said that he 
needed to exercise, that staying in bed all week was boring, and a little shoveling 
would do him good.  After shoveling snow for almost half an hour, he started feeling 
pain in his left shoulder. He was figuring it must be because of the shoveling, so he 
decided to go inside to get some rest. He goes to bed, but feels an intense pain that 
increases towards his left arm and left side of the upper body. He starts screaming in 
pain, waking Mom, who immediately asks him about what is happing, and as soon 
as he tells her about the location of the pain, Mom is calling the emergency. Five 
minutes later nurses from Karolinska University Hospital is knocking on the door. 
The doctors on the phone are telling the nurses that the ECG is showing that Dad is 
having a heart attack and that Dad needs to get to the emergency straightaway. My 
head is spinning around and my heart is beating fast. One question is screaming in 
my head, but I am not finding the courage in saying it out load should the answer be 
something terrible. Instead of asking if he is alive, I decide asking her about where 
  
he is, and she tells me he is resting in bed and is going to have a surgery the next 
coming day.  
 
The doctor had told him that he had had a high blood pressure for which he had 
none treatment for and they had acknowledge the fact that he also had diabetes. 
They initiated pharmacological treatment, talked about lifestyle changes. Dad 
decided that he would fully accept and embrace the doctor’s recommendations, and 
start a new life, which was exactly what he did.  
 
I am so grateful that Mom had done the right thing to call the emergency and that 
Dad had survived.  
 
Dad, so proud of you that you were able to do all those lifestyle changes and that 
you take your medications every day. 
 
Love you. 
 
 
 
  
Miriam Qvarnström    
ABSTRACT 
Hypertension is The efficacy of antihypertensive drug therapy is undisputed, but 
large surveys report that one in four patients reach a target blood pressure of 
<140/90 mm Hg. Although there are several explanations to this problem, poor 
medication adherence and persistence to drug treatment suggests as important 
contributors. 
We started with a cross-sectional study design, to describe drug prescription 
patterns and blood pressure control in 24 primary healthcare centers in 
southwestern part of Stockholm, Sweden. Electronic medical records of 21167 
patients (≥30 years) with a diagnosis of hypertension and a consultation at one of 
the included primary health care centers in 2005-2006 were analyzed. A prescription 
of an antihypertensive drug were found in 89% of the patients, and the most 
common were the diuretics and beta blockers. One out of four primary care patients 
with hypertension had a target blood pressure <140/90 mm Hg with or without 
antihypertensive drug treatment.  
Medication persistence is considered an important factor to poor blood pressure 
control. Therefore, in the subsequent project, we used a cohort study design to 
measure persistence after two years of follow-up and analyzed factors associated 
with low therapy persistence, i.e. persistence to any antihypertensive drug class 
treatment. Using electronic medical records for patients with hypertension in 48 
Swedish primary healthcare centers and data linkage to national registers on 
dispensed drugs, hospitalizations, outpatient hospital consultations, deaths, 
migration, and socioeconomy, we were able to identify 5225 patients initiated on 
antihypertensive drug treatment during 2006- 2007. Among patients with a 
dispensed first prescription, 65 % were persistent after the two years of follow-up. 
Factors associated with low therapy persistence to antihypertensive drug treatment 
were male sex, younger age, mild-to-moderate systolic blood pressure elevation, 
and birth outside of Sweden. 
After the assessment of therapy persistence, an important question remained, and 
that was to answer if there was a difference in persistence to the various 
antihypertensive drug classes? Again, we performed a cohort study with the same 
method described above, but analyzed each antihypertensive drug class in 
comparison to the diuretics. It appeared to be no difference in drug class persistence 
between diuretics and the other major antihypertensive drug classes. Predictors 
behind low class persistence were the same as for therapy persistence. 
Although register studies are of interest and of great value, they lack certain 
information. To get a broader picture of the medication persistence, we decided to 
perform a cross-sectional study and use questionnaires to ask the patients about 
their beliefs about medicines and the hypertension diagnosis. The questionnaires 
were linked with data on the patient’s filled prescription and the patients were 
categorized into persistent or non-persistent medication-users, to observe potential 
differences in the attitudes between the persistent and non-persistent patients. Out 
  
of the 69 primary healthcare centers questioned, 25 agreed to participate in the 
study.  In January 2016, patients with a diagnosis of hypertension and a consultation 
at one of the 25 primary health care centers received a questionnaire 3-12 months 
after initiation of drug treatment. Out of the 1197 patients newly initiated 
antihypertensive drug treatment, 711 patients (59%) responded. Patients were 
classified as persistent (609, 86%) or non-persistent (102, 14%) to antihypertensive 
drug treatment by analyses of their filled prescriptions. Compared to non-persistent 
medication users, patients persistent to medication believed to a higher degree that 
the diagnosis of hypertension was chronic, that it had less consequence on their life, 
that they can prevent cardiovascular disease by taking antihypertensive drug 
treatment and that there is something positive about taking the pharmacological 
treatment. 
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INTRODUCTION 
Hypertension or elevated blood pressure is a common condition, with high 
prevalences in many parts of the world.1 For most patients, it is a condition with 
unknown aetiology and without symptoms. This silent illness can affect the arteries, 
veins, and inner organs for several years without a single notice. If the patient finds 
out about the blood pressure elevation, corresponding to a diagnosis of hypertension 
(≥140/90 mm Hg2), it is possibly during a visit to the pharmacy, primary healthcare 
center, hospital or at home (≥135/85 mm Hg)2. At this point, it can certainly be an 
unpleasant reminder or acknowledgement of the fragile, older body, and the higher 
risk of coronary heart disease, heart failure, stroke, peripheral arterial disease, renal 
failure, and dementia.3-7 If the patient seeks healthcare professional, the patient will 
receive information about the necessary lifestyle changes, to lower the blood 
pressure elevation.  There are patients that decide do these lifestyle changes. They 
lower their  elevated blood pressures as they lose weight8, reduce salt9,10 and 
alcohol intake11, do physical exercise regularly12, and increase the intake of 
vegetables in their diet2, but the majority of patients will need an antihypertensive 
drug prescription and more than one drug class to reach target blood pressure.13 In 
most cases, the patient will fill the first prescription, but as it turns out, many patients 
will not continue to fill their prescriptions.14-19 
Consistent and long-term antihypertensive drug therapy is crucial to maintain blood 
pressure control and benefit from treatment.20 Discontinuation of antihypertensive 
drug treatment is associated with poor blood pressure control.21 These facts are 
problematic, when results from a review report an average medication persistence of 
63% after one year, with a variation from 35-92%.22 This large variation is the 
proportion of patients persistent to drug treatment in later studies from Europe, 
Northern America, Australia and Asia.15,23-27 However, it may be difficult to compare 
studies due to differences in patient populations, time of follow-up, definitions of 
persistence and data sources. 
Although to measure the blood pressure itself is by far the most rational way to study 
if the patient takes the antihypertensive drug, is does not take into account the 
possibility that the patient might be adherent only before the consultation with the 
health care provider. Therefore, data on filled prescriptions from national registers 
are of great value to observe if patients continue on their antihypertensive drug 
treatment.28 However, registries provide limited knowledge on patient behavior. 
Hence, to analyze the actual patient’s attitudes, a questionnaire provide an 
opportunity to investigate the patient’s own beliefs and ideas.  
The studies in this thesis have the aim to: 1) describe blood pressure levels and 
antihypertensive drug treatment, 2) study which factors may be associated with 
patients’ discontinuation of antihypertensive drug treatment and 3) describe 
differences in attitudes between persistent and non-persistent medication users. 
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EPIDEMIOLOGY OF HYPERTENSION AND THE PATIENTS 
In 2004, the Swedish Agency for Health Technology Assessment and Assessment 
of Social Services (SBU) published a report on the prevalence of hypertension with 
an estimate of 27%, which corresponded to 1.8 million of the adult population of 
Sweden over the age of 20 years old.29 Eight years later, the Skaraborg project 
found that 20% of the adult population had hypertension and steep increase in older 
age.30 These two estimates represented proportions of patients expected to have 
hypertension, whether or not diagnosed by a physician, i.e. unknown hypertension. 
The prevalence of hypertension is dependent on the number of blood pressures 
recordings on each occasion, and the number of visits to the health care provider. 
Therefore, results of hypertension prevalence between different populations and 
countries, may be compared with difficulty, and subsequently, it has been suggested 
to use surrogates for hypertension prevalence.31  
The prevalence of hypertension was estimated to 10% in Östergötland County in 
200432, 11% in southwestern part of Stockholm in 2005-200633 and 12% in 
Stockholm County in 201134 of the adult population. These estimates on prevalences 
of known hypertension are based on diagnoses recorded in primary health care as 
well as other caregivers. A study based on data from electronic medical records from 
the primary health care centers of Stockholm County in 2011, found that essential 
hypertension was one of the five most common diagnoses, recorded for almost 6% 
of all the inhabitants in the county during 2011.35 However, although these 
represents different regions of Sweden, differences in prevalences of hypertension 
has been reported between rural and urban areas of Sweden36,37.  
A systematic review from 2004 found that the prevalence of hypertension varied 
widely between countries in the rest of the world, between 3.4% in rural Indian men 
and 72.5% in Polish women.38 The authors estimated that 26.4% of the adult 
population in the world had hypertension in 2000, and 29.2% were predicted to have 
hypertension in 2025. However, a population-based review on the prevalence and 
control of hypertension in 90 countries was published recently in 2016, suggesting 
that 31% of the adult population of the world had hypertension in 2010.1 This review 
defined the countries into low – and high-income countries according to the World 
bank classification system,39 and found that the prevalence in 2010 was 25% in high-
income countries such as Sweden. 
BLOOD PRESSURE 
In 2012, the World Health Organization stated that 17.5 million died from 
cardiovascular disease, which represented almost a third of all global deaths.40 The 
same year the Global Burden of Disease project reported that an elevated systolic 
blood pressure above 115 mm Hg was the largest factor that contributed to the 
global burden of disease and mortality.41 These findings gives us an overview of the 
significant problem we are facing with large populations of patients in need of 
lowering their blood pressure.  
  3 
Older observational studies reported that few patients reached target blood 
pressures42 and that there were differences in the level of blood pressure control 
between countries. The control rates in Europe were found to be worse than those of 
Canada and the United States.43 More positive results come from longitudinal 
observational studies in the populations of Sweden44, Germany45, Czech Republic46  
and in the United States.47 Those studies described a trend in increased proportion 
of patients with a controlled blood pressure over several decades. However, it is 
uncertain if this was due to better treatment or if patients with lower blood pressures 
were getting diagnosis and treatment earlier.  
An overview of the ESH/ESC guidelines for initiation of antihypertensive drug 
treatment according to blood pressure, number of risk factors and disease history 
are provided in Table 1 with relevant year for the studies included in the thesis. The 
corresponding Swedish national guidelines comes from the Medical Product Agency, 
the Swedish national authority responsible for regulation and surveillance of the 
development, manufacturing and marketing of drugs and other medicinal products, 
and they are only slightly modified from the ESH/ESC guidelines.   
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Table 1. Modified summary of blood pressure thresholds for initiating antihypertensive drug 
treatment as stated by other risk factors and disease history according to the ESH/ESC 
guidelines from different years. 
 Blood pressure (mm Hg) thresholds to initiate 
antihypertensive drug treatment 
 ESH/ESC 
guidelines 
(2003)48  
ESH/ESC 
guidelines 
(2007)49 
ESH/ESC 
guidelines 
(2013)2  
No other risk factors SBP ≥140 or              
DBP ≥90                                          
(initiation of drug 
treatment should 
be considered 
after 3-12 months 
of monitoring of 
BP with an initial 
SBP between 
140-179 or DBP 
90-109) 
SBP 140-159    
or
DBP 90-99 
SBP 140-159       
or                     
DBP 90-99 
1-2 risk factors SBP ≥140 or              
DBP ≥90                                          
(after at least 3 
months of 
monitoring of BP 
with an initial SBP 
between 140-179 
or DBP 90-109) 
SBP 140-159    
or
DBP 90-99 
SBP 140-159       
or                     
DBP 90-99 
Diabetes SBP 130-139                 
or                                
DBP 85-89 
SBP 130-139   
or                  
DBP 85-89 
SBP 140-159       
or                      
DBP 90-99 
Established cardiovascular or renal 
disease 
SBP 130-139                 
or                                
DBP 85-89 
SBP 120-129    
or                  
DBP 80-84 
SBP 140-159       
or                     
DBP 90-99 
SBP – systolic blood pressure. DBP – diastolic blood pressure. The ESH/ESC guidelines from 2003 
stated that the initiation of drug treatment should be considered in patients with no other risk factors. 
Patients with no other risk factors are those with low added risk. The ESH/ESC guidelines from 2007 
and 2013 stated that the initiation of drug treatment should be considered in patients with no other risk 
factors if blood pressure is still uncontrolled after several months of lifestyle changes. The ESH/ESC 
guidelines from 2007 and 2013 stated that the initiation of drug treatment should be considered in 
patients with 1-2 risk factors if blood pressure is still uncontrolled after several weeks of lifestyle 
changes.  
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ANTIHYPERTENSIVE DRUG TREATMENT  
In the four studies of this thesis, focus was primarily on the five major 
antihypertensive drug classes; angiotensin receptor blockers (ARBs), angiotensin 
converting enzyme inhibitors, beta blockers, calcium channel blockers and diuretics. 
These five antihypertensive drug classes were all first-line treatment according to the 
ESH/ESC guidelines from 2013, but the regional guidelines provided in Stockholm 
County, the Wise Drug List50, did not recommend beta blockers in 2017. They were 
reduced to second line treatment in previous years. A Cochrane meta-analysis from 
2012 reported that the beta blockers had a worse outcome than some of the other 
antihypertensive drug classes. 51,52  
The five main antihypertensive drugs classes studied in this thesis lower the blood 
pressure (BP) through the cardiac output (CO) and/or the peripheral vascular 
resistance (PVR): 
BP = CO X PVR  
Beta blockers and diuretics were shown to lower the cardiac output, while the 
angiotensin converting enzyme inhibitors, the angiotensin receptor blockers and the 
calcium channel blockers reduced the peripheral vascular resistance. 
Patients 
Evidence suggested that women benefited from antihypertensive treatment similar to 
men.53 Cross-sectional studies of antihypertensive drug treatment from various 
countries around the world reported that diuretics were the most commonly used by 
women, while ACE-I were more common among men.54-58 It was suggested that 
these differences between sexes could not be explained by known factors that 
influenced the choice of initiation of antihypertensive drug treatment and that further 
investigations were needed. Studies of sex differences in indications not registered, 
such as the prescribing of diuretics in ankle edema and experiences of side effects, 
were proposed.55  
In 2008, the Treatment of Hypertension in Patients 80 Years of Age or Older 
(HYVET) concluded that patients 80 years of age or older will benefit from 
antihypertensive treatment.59 A meta-analysis of randomized trials published the 
same year concluded that the antihypertensive drugs are just as effective in patients 
65 years of age or older as in younger patients.60 Also, a recent publication 
investigated if there was an interaction in the antihypertensive treatment and the 
frailty in older patients, and concluded that there was none, but that more studies 
were needed to examine this possible interaction.61  Despite the evidence in favor of 
treatment in patients 80 years or older, findings from a cross-sectional studies  
suggested that older were not treated as aggressive as younger patients.62  
The prevalence of diabetes was found to be 6.8% with an incidence of 4.4 per 1000 
patients in 2013.63 A longitudinal study followed patients with hypertension for 28 
years, and found that 20.4% of the patients developed diabetes.64 These patients, as 
well the obese, had a higher insulin resistance. A problem would therefor arise if we 
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were to treat these patients with the old types of beta blockers or diuretics, since 
they could reduce the insulin sensitivity. Furthermore, beta blockers had shown 
results of increased risk of new-onset diabetes in patients with hypertension.65 The 
ACE-I66 would seem as a better option as they improved insulin sensitivity67 and 
ARBs, or some of the relatively newer vasodilating beta blockers which doesn’t 
seem to impair the insulin sensitivity to such as much as the older substances.68,69  
MEASURES OF MEDICATION TAKING BEHAVIOUR 
Numerous of names and definitions for the various measures of medication taking 
behavior have been used over the years. Although several decades of compliance 
and persistence research, there still has not been developed any uniform standard of 
definitions and measurements. This hampered the possibility to compare the 
different studies, and the complexity increases with the different healthcare policies 
of each country. The most common terms of medication taking behavior used today 
are described in the two sections following, with the definitions based upon the 
review published in 2008 by Joyce Cramer and the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) Medication Compliance and 
Persistence Work Group.70 They developed definitions for the terms compliance and 
persistence during three years of review work and discussions with professionals 
from countries all over the world.  
Four years after Cramer’s review was published, a new review came. It was written 
by Vrijens et.al. with another definition of adherence and persistence.71 Instead of 
defining adherence or compliance as a different measure compare to persistence70, 
they proposed that persistence could be seen as a part of adherence.  
Medication adherence, compliance and concordance 
In 1990, Feinstein published an article about compliance72 were he commented on 
the different terms, saying that : ”Adherence seem to sticky; Fidelity has too many 
connotations; and Maintenance suggest a repair crew. Although adherence has its 
adherents, Compliance continues to be the most popular term.” He was right at the 
time, but around 1993 the term Compliance was replaced by Adherence.73-75 During 
this time there was a change in the way on how we see the relationship between the 
patient and health care provider. Compliance in the English language has a negative 
connotation and means that the patients are subservient to the prescriber 76,77 and 
that the patient is a passive and obedient to the prescriber’s instruction.78,79 The term 
concordance was introduced in 1995 by the Royal Pharmaceutical Society of Great 
Britain.80 The meaning of term acknowledged the fact that patients and health care 
providers may have differing views and therefor need to cooperate.80-83  However, 
around 2008 the term “Medication adherence” became a MeSH term, and according 
to Cramer’s review are the terms medication compliance and adherence 
synonymous.70  
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Medication persistence 
In the review by Cramer70 medication persistence is defined as : “the duration of time 
from initiation to discontinuation of treatment”. In this definition, a predefined gap 
should also be determined. The gap is the number of days between start and end of 
medication or observation, where the patient is allowed to be without drug treatment 
but is considered persistent. This definition has been used in all three studies on 
medication persistence included in this thesis.  
A summary of selected publications on medication persistence on antihypertensive 
drug treatment are summarized in Table 2. The table is merely an overview of how 
different the published articles on medication persistence can appear. Medication 
persistence can further be divided into therapy or class persistence. There are no 
established definitions for these two terms, but in general, therapy persistence 
describes the studying of any antihypertensive drug class and if patients switch drug 
class, they are still considered therapy persistent.  
Class persistence, on the other hand, is when you want to study medication 
persistence to a certain antihypertensive drug class, and if the patient switch to 
another antihypertensive drug class, the patient is considered non-persistent to the 
drug treatment. Systematic reviews on studies of medication persistence to 
antihypertensive drug treatment showed major differences in results.22,84 They also 
reported large differences in used definitions of persistence to antihypertensive drug 
treatment and methods used. This results in severe difficulties in comparing the 
results between studies, and also leads to large variations in the findings. The 
source of information which has been suggested to be the golden standard for the 
assessment of persistence to drug treatment are the databases on filled 
prescriptions85, primarily from national databases, since they provide unique source 
of complete follow-up of drug dispensing.  
Several studies have analyzed persistence to antihypertensive drugs using data 
from various prescription- or dispensing databases, but without any linkage to 
diagnoses. These studies may be difficult to interpret in the context of hypertension 
since they also include antihypertensives prescribed for many other conditions. 
Some examples include beta blockers prescribed for migraine or atrial fibrillation, 
ACE-I/ARB prescribed for heart failure or diuretics prescribed for edema.  
Persistence may be influenced by many patient-, provider or health system 
characteristics. A majority of studies include age, sex and comorbidity in the 
analyses. Others have analyzed adherence and persistence in relation to patient 
characteristics such as number of drugs, concomitant medication, level of insurance, 
income, living area, ethnicity, social insurance, health status, education and marital 
status or provider characteristics such as organization of the clinic or physician 
education specialty and qualifications. An overview of the determinants included in 
the studies from Table 2 are presented in Table 3.  
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Table 2. Overview of different studies on persistence to antihypertensive treatment. 
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filled prescriptions 
Time  
period  
between  
pre-
scriptions 
issued 
Time 
between  
filled pre-
scriptions 
Time  
between  
end of  
supply 
and new 
filled 
pre-
scription 
Bourgault et.al. 
(2005)18 
60 
 
21 326 T 29-53 3  X  
Elliott et.al. (2007)86 60 685 C 56-69 1   X 
Ishisaka et.al. (2012)16 51 772 C 58-69 3.5   X 
Ah et.al. (2015)17        
Friedman et al. 
(2010)23 
207473 T/
C 
66 2   X 
Patel et al. (2007)87 242 882 C 30-52 1   X 
Burke et al. (2006)88 90 109 454 T 7 9    
Tamblyn et al. 
(2010)89 
13 205 T 78 0.5   X 
Vinker et al. (2008)90 3 799 C 41 3  X  
Corrao et.al. (2008)19 445 356 T/
C 
50 5   X 
Simons et.al. (2008)26 48 690 T 44 <3  X  
Briesacher et.al. 
(2007)l91 
23 047 C 52-73 1  X  
Nicotra et.al. (2009)25 49 805 C 76 3/4   X 
Saleh et.al. (2008)92 22 821 C 43 1   X 
Hasford et.al. (2007)24 180 13 763 T/
C 
15 3 X   
Wong et.al. (2009)93 93 286 T 87 0.5 X   
van Wijk et.al. 
(2005)27 
2 325 T 61 10   X 
Lachaine et.al. 
(2008)94 
n/a 4 561 T 53-69 2  X  
Mancia et.al. (2014)95 n/a 493 623 T 57 1   X 
Grimmsmann et.al. 
(2014)14 
n/a 9 513 T 44-82 4 X   
Selmer et.al. (2012)15 n/a 78 453 T 65-96 5  X  
Trimarco et.al. 
(2012)96 
n/a 2 409 C n/a >2  X  
Allowed gap is the number of predefined days in which the patient is allowed to be without treatment, 
but is still considered persistent. End of supply can be estimated from the actual dosage text or the 
less precise measure DDD (Defined Daily Dose); the assumed average maintenance dose per day for 
a drug used for its main indication in adults (problem here is that all of the antihypertensive drug 
classes do not have DDD’s for the indication of hypertension). 
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Table 3. Number of studies assessing the various variables in association to persistence to 
antihypertensive drug treatment. 
Assessed variable Number of studies 
Sex 18 
Age 18 
Comorbidity 12 
Income 5 
Country of birth/immigrant 1 
Initial blood pressure 1 
Education 0 
An overview of the determinants included in the studies from Table 2 are presented here. 
 
SPCCD – THE SWEDISH PRIMARY CARE CARDIOVASCULAR DATABASE 
In December 2007, a collaboration started with of a group of ten highly devoted 
researchers, including cardiologists, general practitioners, pharmacists, PhD 
students and data managers from Stockholm, Gothenburg and Skövde, with the goal 
of creating a research database consisting of patients with diagnosis of hypertension 
in the primary health care. After five years of devotion into work and meetings, the 
Swedish Primary Care Cardiovascular Database was created. The database has 
provided data for the involved researches since 2012, and other researches 
interested in the data may send a request to the board to ask permission on using 
the data for scientific use only. A list of all publications from the SPCCD by 
publication year is provided in Table 4. 
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Table 4. List of publications from the Swedish Primary Care Cardiovascular Database 
Study Diagnoses  Main finding 
Qvarnström M, et al. 201133 Essential hypertension Antihypertensive drug treatment and 
control according to sex, age and 
comorbidity 
Qvarnström M. et al. 201397 Essential hypertension Therapy persistence to 
antihypertensive drug treatment 
Hasselström J. et al. 201498 Essential hypertension Descriptive data of the SPCCD 
Ljungman C. et al. 201456 Essential hypertension Gender differences in antihypertensive 
drug treatment 
Ljungman C. et al. 201599 Essential hypertension Antihypertensive treatment and control 
according to gender, education, 
country of birth and psychiatric 
disorder 
Qvarnström M. et al. 2016100 Essential hypertension Class persistence to antihypertensive 
drug treatment 
Holmqvist L. et al. 2016101 Treatment resistant 
hypertension 
Prevalence of treatment resistant 
hypertension 
Bokrantz.T. et al. 2017102 Essential hypertension 
and osteoporotic 
fractures 
Thiazide diuretics and the risk of 
osteoporotic fractures in hypertensive 
patients 
SPCCD – Swedish Primary Care Cardiovascular Database.  
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AIMS 
The overall aim of this thesis was to add knowledge about antihypertensive drug 
treatment and medication persistence in primary health care patients. 
The main objectives of the studies of this thesis: 
1. To describe the antihypertensive pharmacological treatment 
prescribed and blood pressures levels. 
2. To assess therapy persistence for antihypertensives and to assess 
factors associated with poor therapy persistence.   
3. To assess differences in class persistence between the various 
antihypertensive drug classes. 
4. To assess differences in attitudes towards hypertension, drugs in 
general and the antihypertensive drug treatment in persistent and 
non-persistent patients.
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MATERIALS AND METHODS 
This thesis consists of four observational studies on patients with diagnosis of 
hypertension in primary health care. An overview of the materials and methods used 
in this thesis are presented in Table 5.  
STUDY DESIGNS 
The thesis comprises two different study designs, the cross-sectional and the cohort 
(Figure 1 and 2). In a cross-sectional study design, all information obtained for the 
study is gathered at the same time point. It means that the information that the 
results can rely upon in this type of study design, is limited to this specific time, and 
gives only a snapshot of the population under study. Conclusions possible to draw 
from such study designs are limited to the prevalence of the population and potential 
associations between various factors and variables. It is useful when there is a need 
to give a general description of a population, but cannot be used for studying casual 
relationships, where patients need to be followed over time and data on what 
happened before and after is needed.  
 
Figure 1. The two study designs of the thesis; the cross-sectional and the cohort. 
 
Black and white triangles represents two different exposures examined in this thesis, for example men 
and women. In the cross-sectional study design from Study I, a prevalence of hypertension was 
estimated, and in Study IV, attitudes towards hypertension at time T0. The cohort studies in this thesis 
investigated persistent versus non-persistence to drug treatment as the outcomes of interest, 
measured from T0 until time Tx, and corresponds to two years in the studies of this thesis. 
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CCB – calcium channel blockers. ACE-I – angiotensin converting enzyme inhibitor. ARB – angiotensin 
receptor blocker. Study period includes the years of inclusion period and the time of follow-up.  
 
An example of such study design is the cohort study design. In a cohort study, a 
defined group of people without the outcome of interest is being analyzed and 
Table 5. Overview of the studies included in the thesis. 
Study I II III IV 
Design Cross-sectional Cohort Cohort Cross-sectional 
Setting 24 primary 
health care 
centers in south-
western part of 
Stockholm 
24 primary health 
care centers in 
south-western part 
of Stockholm and 
24 primary health 
care centers in 
Skövde district in 
Western Sweden 
24 primary health 
care centers in 
south-western part 
of Stockholm and 
24 primary health 
care centers in 
Skövde district in 
Western Sweden 
25 primary health 
care centers in the 
north-eastern and 
south-western part 
of Stockholm 
Hypertension 
diagnosis 
2005-2006 2001-2007 2001-2007 2013-2015  
Number 21167 5225 4997 711 
Data 
source(s)  
Electronic 
medical records 
from primary  
The Swedish 
Primary Care 
Cardiovascular 
Database 
The Swedish 
Primary Care 
Cardiovascular 
Database 
Questionnaires 
merged with the 
national register on 
dispensed drugs 
Study period 2005-2006 2006-2010 2006-2010 2013-2016 
Main factors 
analyzed 
Blood pressure 
in all 
hypertensive 
patients and 
patients with 
diabetes. 
Prescribed 
antihypertensive 
drug treatment  
Persistence to any 
antihypertensive 
drug treatment 
Persistence to 
antihypertensive 
drug classes 
(diuretics 
compared to beta 
blockers, CCBs, 
ACE-Is or ARBs) 
The patients’ 
attitudes towards 
diagnosis of 
hypertension and 
drugs in relation to 
their persistence to 
antihypertensive 
drug treatment 
Data analysis Student’s t-test Cox model Cox model Mann-Whitney U-
test and Cox 
model 
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followed forward in time, starting at the date when the exposures were defined. The 
outcome of interest in these cohort designs of this thesis (Study II-IV) is the date 
when the patient is defined as non-persistent to antihypertensive drug treatment. 
Patients are censored (further discussed under “Methods”/”Cox regression”) when 
they die or when the end of study period, corresponding to a maximum of two years 
(Study II-III). 
SETTINGS 
The thesis includes patients from three settings, marked out on the map of Sweden 
in Figure 3. The setting in Study I included 24 primary healthcare centers of 
southwestern Stockholm, Sweden, all of which are part of a collaboration since 
1992103. The group EK-gruppen, consisting of five general practitioners interested in 
improving the quality of drug prescription started the collaboration. They agreed on 
how diagnoses and quality parameters should be registered in the medical records 
and data from the medical records were used in feedback to the primary healthcare 
centers to discuss potential areas of quality improvement. The second setting was 
used in Study II and III, comprising of patients from the southwestern part of 
Stockholm and the Skövde district, representing an urban and a rural area, with a 
total of 48 primary health care centers, equally distributed between the areas. These 
patients were all collected from the Swedish Primary Care Cardiovascular Database 
(SPCCD), including a combination of electronic medical records data and national 
registers for the 48 primary health care centers. The third setting comprised of 
patients consulting primary health care centers from the southwestern and 
northeastern part of Stockholm, representing two different socioeconomic areas.  
EPIDEMIOLOGY AND PATIENTS  
The patients were 30 years or older and had consulted and received a diagnosis of 
essential hypertension (ICD-10 code I10) at one of the primary health care centers 
included in the studies of this thesis (Study I-IV). The patients’ were newly initiated 
on antihypertensive drug treatment from one of the primary health care centers 
involved in the studies (Study II-IV), or included all patients diagnosed with 
hypertension irrespective of patients being prevalent or incident antihypertensive 
drug users, or not prescribed an antihypertensive drug at all (Study I). The 
prevalence of hypertension was calculated. The number of patients with diagnosed 
hypertension was divided with the number of people in the catchment area during 
the study period of 2006 (Study I). 
VARIABLES  
Variables assessed or described in the studies of this thesis are summarized in 
Table 6.  
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Table 6. Variables described or assessed in the studies of this thesis. 
 Study I Study II Study III Study IV 
Age X X X X 
Sex X X X X 
Blood pressures (mean recorded)  X    
Blood pressures (last recorded) X X X X 
ACE-inhibitors X X X X 
Angiotensin receptor blockers X X X X 
Beta blockers X X X X 
Calcium channel blockers X X X X 
Diuretics X X X X 
Fixed combination therapy X  X  
More than one drug class prescribed X  X  
Cardiovascular comorbidity X X X X 
Atrial fibrillation X X X  
Congestive heart failure X X X  
Diabetes mellitus  X X X X 
Ischemic heart disease X X X  
Stroke/TIA X X X  
Number of other drugs  X X  
Educational level  X X  
Country of birth X X X X 
Income  X X  
Attitudes towards hypertension    X 
Attitudes towards drugs in general    X 
Attitudes towards antihypertensive drug 
treatment 
   X 
Cardiovascular comorbidity – a diagnosis of atrial fibrillation, congestive heart failure, diabetes 
mellitus, ischemic heart disease or stroke/TIA. We analyzed prescribed drug classes (Study I) and 
filled prescriptions (Study II-IV). 
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DATA SOURCES 
The data sources of this theses comprised of national registers held by the National 
Board of Health and Welfare and Statistics Sweden, the electronic medical records 
provided by the primary health care centers and the Swedish Primary Care 
Cardiovascular Database (SPCCD).  
Figure 2. Map of Sweden highlighted with the three settings of this thesis and data on primary 
health care centers. 
 
Red area – representing Study I. Yellow and red areas – representing Study II-III (the settings of the 
Swedish Primary Care Cardiovascular Database). Blue area – representing Study IV. 
 
Swedish Prescribed Drug Register 
The Swedish Prescribed Drug Register contains information about filled 
prescriptions from primary and specialized care, including data from all pharmacies 
in Sweden since July 2005104. The data on each prescription is ordered by the drugs 
Anatomic Therapeutic Classification code and date of filled prescription. The 
information is updated monthly and comes from the E-health authority, to which the 
pharmacies are obliged to inform about sell statistics and prescribed drugs according 
to law (2009:366, 1996:1156)105,106. The Swedish Prescribed Drug Register is a 
unique source of information, since it also includes the patients ID-number, making it 
possible to link patient information from this register with other registers and 
databases107. The register provided information on age, sex, filled prescription, and 
date of filled prescription, dosage text, number of tablets dispensed and strength of 
the dispensed drug (Study II-IV). Problems faced when using the register for 
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analyzing chronic medication is the way the Swedish reimbursement system work for 
these types of drugs. It encourage patients to fill their prescriptions when they have 
reached top payment for the drugs, and receives the drugs for free. This may lead to 
hoarding of drugs and moreover, patients may fill their prescriptions irregular due to 
this system. It is also important to acknowledge that some elderly residents in 
nursing homes may receive prescriptions from stock orders and, consequently, their 
medications may not be included in the register. Other difficulties with this register is 
the lack of information about the indication for which the drug has been prescribed 
and the fact that the dosage text is unstructured or may be missing for many 
prescriptions. 
National Patient Register 
The register includes data on main and supplemental diagnoses according to ICD 
codes and surgical treatments for each patient visit to hospitals in Sweden. The 
register is held by the National Board of Health and Welfare, which started in the 
1960’s to collect data on patients in the public hospitals. Since 1984 it is mandatory 
for all county councils in Sweden to participate, and data on all in-patient care in the 
country is provided since 1987, while out-patient care consultations has been 
provided since 2001108. Today all of the 21 county councils in Sweden report the 
data monthly to the National Board of Health and Welfare. The in-patient data is 
estimated to have almost 100% coverage. The out-patient data has much lower 
coverage and estimated to around 80%, which has been suggested to be explained 
by the lower reporting of diagnoses by the private health care108.  In this thesis, 
information from the National Patient Register was used in Study II and III, where the 
SPCCD was the data source, to include the main and supplemental diagnoses from 
hospitals. The register lack information about visits to primary health care centers, 
and therefore underestimates diagnoses such as hypertension which is managed 
and detected primarily by general practitioners. 
Cause of Death Register 
The register is held by the National 
board of Health and Welfare and 
provides information about the cause of 
death. The register includes data on the 
cause of death for patients registered in 
Sweden, with corresponding 
international ICD code. The data is 
updated yearly.  
Statistics Sweden  
Data on country of birth, educational 
level, income of the Swedish citizens 
and population living in the municipals 
of Sweden are held by Statistics 
Sweden since 1985, and is updated 
yearly.  
Electronic Medical Records 
Electronic medical records contain information about the medical history of the 
patient from one practice and is stored digitally. Information about diagnoses, blood 
pressures, and prescriptions was used for the four studies in this thesis. Heads of 
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the primary health care centers gave written approval for data extraction from the 
medical records.  
SPCCD (Swedish Primary Care Cardiovascular Database) 
The research database SPCCD contains information on 74751 patients with 
diagnosis of hypertension from 48 primary health care centers in southwestern part 
of Stockholm and Skövde-district in region Västra Götaland.98 The two geographical 
areas represents an urban and a rural area of Sweden, respectively. They have 
used the same methods for extracting data on consultations, clinical and laboratory 
data, diagnoses and prescribed medications, making it possible to link the data 
together. The data is stored on a virtual server at the University of Gothenburg 
(Windows server 2008 R2, Microsoft Corp., Redmond, WA, USA).98 The database 
also contains information from the national registers of Sweden and the patients’ 
identification number, facilitating the linkage of data between the data sources. The 
casserole of SPCCD data is illustrated in Figure 3.  
 
Figure 3. The Swedish Primary Care Cardiovascular Database 
 
ID – identification number of the patient. All Swedish citizens have their own unique identification 
number, and it is recorded in the national registers and medical records. The ID number facilitates 
linkage of data between the registers and electronic medical records   SCB – Statistics Sweden. 
SPCCD – Swedish Primary Care Cardiovascular Database. 
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Questionnaires 
In Study IV, questionnaires filled by patients newly initiated on antihypertensive drug 
treatment was used as data source. The questionnaire contained a total of 30 
questions and space for general comments by the patients (see Appendix). There 
were six general questions about sex, antihypertensive treatment and blood 
pressure measuring, if born in Sweden and side effects, eight questions from the 
Brief-Illness Perception Questionnaire (IPQ)109 and twenty-two questions from the 
Belief about Medicines Questionnaire (BMQ)110.  
The Brief-IPQ is a validated questionnaire used for assessing attitudes towards 
diagnoses, and stems from the Illness Perception Questionnaire – Revised, which 
contains 80 questions. 111 The Brief-IPQ contains nine questions, including eight 
single-item questions that are answered on a continuous linear scale from 0-10, and 
one last ninth question that asks about the most likely causes of the disease. The 
ninth question was not included in the questionnaire, since the purpose was to 
analyze quantitative research.   
To assess attitudes towards drugs in general and the specific prescribed 
antihypertensive drug treatment, the BMQ was used as source of information. It 
contains two parts with one section asking twelve questions about general beliefs 
about drugs and the other section contains ten questions that examines attitudes 
towards the actual specific treatment of interest, which here corresponds to the 
antihypertensive drug that has been prescribed.  
MEASUREMENT OF PERSISTENCE 
In all studies of this thesis, except for Study I, persistence was measured and the 
same method of calculating was used. To determine the persistence, the dosage 
texts from the Swedish Prescribed Drug Register was read, either by detection of 
prespecified algorithms or manually. As the dosage texts were read, they were 
translated into variables of number of tablets prescribed and days of treatment. The 
patients were followed for a maximum of two years. A gap of 30 days between end 
of supply of the drug dispensing and the next filled prescription was applied for all 
persistence calculations. For a patient to be classified as non-persistent, the patient 
had not filled the next prescription with less than 30 days of non-treatment, eg. gap. 
In addition, if patients filled a prescription before end of the tablets of the former filled 
prescription, the tablets remaining were accumulated to the next prescription. 
STATISTICS 
All calculations were performed in SAS version 9.2 and 9.4 (SAS Institute Inc., Cary, 
NC, USA), except for Study I, where Microsoft Office Excel and Stata version 10.1 
(College Station, TX, USA) was used. Statistical significance was assumed when p 
<0.05. 
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Descriptive statistics 
The results from Study 1 and the descriptive analysis of Study II-IV were presented 
as percentages, means, medians, standard deviations and interquartile ranges. We 
used the Chi-square test and the Students t-test for comparisons of two groups.  
Survival analysis 
To estimate the time in days when the patient became non-persistent to the initiated 
antihypertensive treatment, we used survival analysis, also called time-to-event 
analysis (Study II-IV). Often, especially when longer time of follow-up (Study II-III), it 
is important to take into account censoring. It is an analytical problem and occurs in 
our studies when the lack of information about when the exact time when the patient 
became non-persistent and occurs when the study ends before the patient becomes 
non-persistent, the patient dies, is hospitalized more than 21 days or is put on 
individual dosing dispensed services. To illustrate survival analysis, it is common to 
use the Kaplan-Meier curves. It is a method where each patient gets three variables; 
their serial time, if they have become non-persistent or censored and which 
exposure group they are in. Here, study group refers to the studied exposures, for 
example women and men. The patients are followed over time, and two things can 
happen to them, either they become non-persistent or they are censored. Survival 
analyses offers many advantages over standard logistic regression for studying 
persistence, such as adjustments for right-censoring and varied duration of follow-
up.112 
Cox (Proportional Hazards) regression 
We used Cox regression to assess associations between persistence and different 
patient characteristics, blood pressures and socioeconomical factors (Study II-III). It 
is expressed in hazard ratios (HR) when we are comparing two exposure groups and 
assumes that the ratio of the hazards remains constant over time.  
Mann-Whitney U-test 
To test for differences in attitudes of hypertension diagnosis and drugs between 
persistent and non-persistent medication users, the non-parametric Mann-Whitney 
U-test was used on the Likert-type scales. It tests if it is equally likely that a randomly 
selected value from one of the Likert type scales in the persistent group will be less 
than or greater than a randomly selected value from one of the Likert type-scales in 
the non-persistent medication-taking group.  
ETHICS 
The studies of this thesis was approved by the Regional Ethical Review Board in 
Gothenburg (dnr 569 – 08) and the Regional Ethical Review Board at Karolinska 
Institutet (dnr 2015/589-31/4). Written consent was obtained for all primary health 
care centers. 
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In all studies of this thesis, data from electronic medical records were used. These 
data are only available to the consulted general practitioner and the head of the 
primary health care center according to Swedish law. Therefore, all the heads of the 
involved primary health care centers gave their written consent for us to use the data 
for our study.  
The data for all studies in this thesis were anonymous in the delivered file.  
All patients received written information about the aim and utility of the study (Study 
IV). They were also informed that no information would be traceable to a single 
individual, that the study was voluntary and would not affect the health care that they 
would receive in the future and that they could withdraw consent at any time by the 
phone number given in the questionnaire.  
The patients were sent a questionnaire from the consulted primary health care 
center. The patients might feel that the questions regarding their attitudes towards 
the diagnosis of hypertension, medicines in general and their antihypertensive drug 
treatment to be sensitive (Study IV). Analyzes of register based data may also be 
sensitive for the patient, although the data is anonymous (Study I-IV). To minimize 
this risk, we informed the patients that their participation was voluntary. We believed 
that the risk of personal encroachment was small and that the benefits of new 
knowledge about how to improve pharmacological treatment of hypertension is 
large. 
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RESULTS 
EPIDEMIOLOGY OF HYPERTENSION AND PATIENTS 
The prevalence of hypertension in 2005-2006 was estimated to 11% in the 
catchment area of the primary health care centers in the southwestern part of 
Stockholm. The catchment area represented populations of 197 000, aged 30 years 
or older.  
An overview of the patient characteristics of the study populations included in this 
thesis are presented in Table 7.    
 
Table 7. Overview of the patient characteristics included in the studies of this thesis. 
Study I II-IIIa IV 
Women, % 58 55 50 
Mean age, years 66±15 61±13 62±12 
Diabetes mellitus, % 21 9 7 
Cardiovascular comorbidity, % 40 16 5 
Born in Sweden, % n/a 76 69 
aStudy II-III – same population of patients. The diagnosis of diabetes mellitus and cardiovascular 
comorbidity came from electronic medical records from the primary health care centers and the 
National Patient Register, while Study IV only had data from the electronic medical records from the 
primary health care centers. Cardiovascular comorbidity – diagnosis of atrial fibrillation, diabetes, 
heart failure, ischemic heart disease, or stroke/transient ischemic attack 
 
The mean age and the proportion having a diagnosis of diabetes or cardiovascular 
comorbidity was highest when both incident and prevalent medication users with 
hypertension were included (Study I). This is in contrast to the studies only including 
patients newly initiated on antihypertensive drug treatment (Study II-IV). The 
proportion of patients born outside Sweden was higher in the register studies (Study 
II-III) compare to the questionnaire-based study (Study IV). 
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BLOOD PRESSURES 
Attainment of target blood pressure 
In 2005-2006, a total of 27% of the patients in south-western part of Stockholm 
reached a target blood pressure of <140/90 mm Hg. The proportion of patients with 
a normal or grade 1-3, according to the ESH/ESC guidelines49, of the mean diastolic 
or systolic blood pressures taken during the study period, are illustrated in Figure 4.  
The last recorded diastolic and systolic blood pressures in the study according to 
severity of hypertension are shown In Table 8. 
 
Figure 4. The mean recorded diastolic and systolic blood pressures according to severity of 
hypertension in 2005-2006 (Study I). 
 
DBP – Diastolic blood pressures. SBP – Systolic blood pressures. SBP normal – a systolic blood 
pressure below 140 mm Hg. Grade 1-3 -  
 
For patients with diabetes mellitus with a target blood pressure of <130/85 mm Hg at 
the time, an overall 7% achieved this goal.  
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Table 8. Severity of hypertension in women and men (Study I) from 2005-2006 according to 
ESH/ESC guidelines from 2007.49 
 Women Men Total 
Blood pressures (mm Hg) N/value % N/value % N/value % 
Mean SBP mm Hg 150.6  149  149.9  
Mean DBP mm Hg 83.8  85.3  84.4  
High normal - normal (DBP <90) 7797 73.5 5295 67.1 13092 70.8 
Grade 1 (DBP 90-99) 2188 20.6 1909 24.2 4097 22.1 
Grade 2 (DBP 100-109) 543 5.1 548 6.9 1091 5.9 
Grade 3 (DBP ≥110) 86 0.8 136 1.7 222 1.2 
High normal - normal (SBP<140) 2470 23.3 2051 26 4521 24.4 
Grade 1 (SBP 140-159) 5071 47.8 3842 48.7 8913 48.2 
Grade 2 (SBP 160-179) 2427 22.9 1569 19.9 3996 21.6 
Grade 3 (SBP ≥180) 646 6.1 426 5.4 1072 5.8 
ISH (SBP ≥140 DBP <90) 5512 51.9 3419 43.3 8931 48.3 
Normal (SBP<140 DBP <90) 2286 21.5 1876 23.8 4162 22.5 
Grade 1 (SBP 140-159 DBP 90-99) 1050 9.9 1024 13 2074 11.2 
Grade 2 (SBP 160-179 DBP 100-109) 248 2.3 268 3.4 516 2.8 
Grade 3 (SBP ≥180 DBP ≥110) 50 0.5 71 0.9 121 0.7 
Mean recorded blood pressure values for 18 502 patients, 10614 women and 7888 men 
corresponding to 87% of the total study population of 21167 patients in Study I. DBP – Diastolic blood 
pressure. SBP – Systolic blood pressure. ISH – Isolated systolic hypertension. 
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Mean systolic and diastolic blood pressure  
The mean systolic blood pressure was 148±20 mm Hg in women and 147±18 mm 
Hg in men (Study I), including patients newly initiated on antihypertensive treatment 
and prevalent users. When only the patients newly initiated on antihypertensive 
treatment were included, the mean systolic and diastolic blood pressures were 
167±20 mm Hg and 92±11 mm Hg in women and 166±20 mm Hg and 95±12 mm Hg 
in men (Study II-IV). Corresponding values for the mean systolic and diastolic blood 
pressures in Study IV were 160±18 mm Hg and 93±11 mm Hg in women and 
160±18 mm Hg and 94±12 mm Hg in men, respectively. The overall mean systolic 
and diastolic blood pressures with standard deviations are illustrated in Figure 5. 
 
Figure 5. Mean systolic and diastolic blood pressures in the four studies of this thesis. 
 
Blue dots – mean systolic blood pressure with error bars representing standard deviation. Red dots – 
mean diastolic blood pressure with error bars representing standard deviations. 
 
ANTIHYPERTENSIVE DRUGS 
The prevalence of prescribed antihypertensive drug treatment was 89% of the 
patients (89% women, 88% men) diagnosed with hypertension in the south-western 
part of Stockholm in 2005-2006 (Study I). The antihypertensive drug classes 
prescribed according to number of classes are presented in Table 9.  In Study I, the 
patients included were both incident and prevalent antihypertensive drug users. 
More than half of the patients were prescribed two or more antihypertensive drugs. 
The most common antihypertensive drug class prescribed at the time of the study 
(2005-2006) were the beta blockers and diuretics.  
An overview of the drug classes prescribed to the patients newly initiated on 
antihypertensive drug treatment are shown in Table 10 and is illustrated in Figure 6 
according to sex (Study II-IV).  
0
20
40
60
80
100
120
140
160
180
200
Study I Study II-III                   Study IV
mm Hg
  27 
Table 9. Proportions of women and men newly or previously initiated on antihypertensive 
drug therapy or without pharmacological treatment in 2005-2006 according to number of 
drug classes (Study I). 
Prescribed antihypertensive drug therapy  Women  Men Total 
 N 12 189 8 978 21 167 
None  10.8 11.7 11.2 
Monotherapy  34.9 32.7 34 
Beta blocker   11.2 10.7 11 
Diuretic  10.8 5.2 8.4 
ACE-I  4.6 8.8 6.4 
CCB  4.3 4.1 4.2 
ARB  3.9 3.9 3.9 
Combinations of two drug classes 
 
34.4 32.1 33.4 
Beta blocker + diuretic  10.8 5.8 8.7 
Beta blocker + CCB  5.1 6 5.5 
Diuretic + ACE-I  4.8 5 4.9 
Diuretic + ARB  4.5 3.9 4.2 
Beta blocker + ACE-I  2.6 4.5 3.4 
Diuretics + CCB  3.2 1.8 2.6 
Other antihypertensive drug combinations  3.5 5.1 4.2 
Combinations of three drug classes 
 
16 17.4 16.6 
Beta blocker + diuretic + ACE-I  3.7 4.5 4.1 
Beta blocker + diuretics + ARB  3.7 2.9 3.4 
Beta blocker + diuretics + CCB  3.6 2.6 3.2 
Diuretic + ACE-I + CCB  1.4 2 1.7 
Diuretic + ARB + CCB  1.7 2.2 1.9 
Other antihypertensive drug combinations  1.9 3.2 2.4 
Combinations of four-five drug classes  3.9 6.1 4.8 
Beta blocker + Diuretic + ACE-I + CCB  1.7 3.1 2.3 
Beta blocker + Diuretic + ARB + CCB  1.7 2.1 1.9 
Other antihypertensive drug combinations  0.5 0.9 0.7 
ACE-I – Angiotensin converting enzyme inhibitor. CCB – Calcium channel blocker. ARB – Angiotensin 
receptor blocker.  
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Table 10. Overview of the drug classes prescribed to the patients newly initiated on therapy 
(Study II-IV). 
Study II-III IV 
Year of prescription 2006-2007 2015 
Antihypertensive drug therapy   
Angiotensin converting enzyme inhibitor 39 44 
Angiotensin receptor blocker 5 16 
Beta blocker 23 7 
Calcium channel blocker 8 23 
Diuretics 31 2 
Fixed combinations 2 3 
More than one drug prescribed 3 6 
Fixed combinations – two various antihypertensive drug classes combined in one tablet, e.g. diuretics 
and angiotensin converting enzyme inhibitors. 
 
Figure 6. Drug classes prescribed to women and men newly initiated on therapy (Study II-IV). 
 
ACE-I - Angiotensin converting enzyme inhibitors. ARB – Angiotensin receptor blockers.  
Diuretics
Beta blockers
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  29 
PERSISTENCE TO ANTHYPERTENSIVE MEDICATION  
Therapy and class persistence to antihypertensive medication 
The overall therapy persistence after two years of follow-up was estimated to 63% 
(Study II) and class persistence to 44% (Study III). This gave us an approximation of 
the proportion of patients switching, corresponding to 19%. This is illustrated in 
Figure 7. Our other calculated estimate of switching was 25 % (Study III).  
 
Figure 7. Proportion of patients’ therapy or class persistence to antihypertensive drug 
treatment according to sex (Study II and III).  
 
Kaplan - Meier curves of the measured discontinuation of any antihypertensive drug treatment 
(therapy persistence) and drug class (class persistence) in Study II and III according to sex. The “fall” 
after 60 days and 130 days is explained by patients not filling their second prescription after a 
prescription of tablets for 30 or 90 days, respectively. 
 
Factors associated with low therapy and class persistence 
The patient characteristics and socioeconomical factors that may influence 
persistence to antihypertensive drug treatment were observed to better understand 
reasons for why patients stop filling their prescriptions (Study II and III). Also, the 
differences in attitudes between persistent and non-persistent patients were 
examined. These variables are listed in Table 11. Male sex, young age, born outside 
Sweden and mild-to-moderate elevated blood pressure were associated with a lower 
therapy persistence. The same factors were also important predictors for low class 
persistence. No major difference in class persistence between diuretics and the 
other antihypertensive drug classes were found.  
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Table 11. Various factors examined in association to persistence in three of the studies of 
this thesis (Study II-IV) 
Study II III IV 
Sex X X X 
Age X X X 
Diastolic blood pressure X X X 
Systolic blood pressure X X X 
Diabetes mellitus X X X 
Cardiovascular comorbidity X X X 
Number of other drugs X X  
Education X X  
Income X X  
Country of birth X X X 
Patients attitudes towards their hypertension diagnosis   X 
Patients attitudes towards medicines in general   X 
Patients attitudes towards their antihypertensive drug treatment   X 
Number of other drugs – filled prescriptions of other drugs than antihypertensives.  
 
Attitudes towards hypertension and pharmacological treatment 
All the results on attitudes towards the hypertension diagnosis, pharmacological 
treatment in general and the specific prescribed antihypertensive drug treatment are 
presented in Manuscript (Study IV). 
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METHODOLOGICAL CONSIDERATIONS 
STUDY DESIGN AND GENERALIZABILITY 
Observational studies using registries provide the opportunity to investigate the 
quality of prescribing and dispensing of medicines in large complete populations. 
The studies in this thesis included all patients diagnosed with hypertension in a large 
number of primary care practices representing both urban and rural settings with 
different socioeconomic compositions. The first study included data collected from 
medical records, while the other studies included individual level data from the 
Swedish Prescribed Drug register on all prescription drugs dispensed to the patients 
included in the studies. Such a complete coverage of patients and their medication 
use increases the external validity and the generalizability of the findings. It is 
important, though, to emphasize that there may be differences in patient 
characteristics, healthcare organization, and guidelines that might limit the 
generalizability of studies to other settings. 
Study I and IV had cross-sectional study designs, while Study II and III had a cohort 
design. Cross-sectional studies describe the utilization of drugs in populations at a 
certain point in time. It is important to acknowledge that since these studies lack 
information on whether the factor of interest precedes or follows the effect they may 
not be used to draw any conclusions on cause and effect.  
In a cohort study, subjects are included based on their exposure to a factor, and 
followed over time. This study design is a preferred choice in persistence research to 
assess discontinuation rates and identify factors associated with discontinuation, 
switching or combination of therapy. Still there are many methodological challenges 
around the definition of these outcomes (see further below). 
VALIDITY IN DATABASES  
There is no perfect way to measure patient persistence. Methods that rely on 
patients’ self-reporting are biased by the fact that patients do not remember or want 
to give the most “correct” answer, thinking that their answers will influence their 
future consultations with their doctor. Further, methods based on measurements 
taken during a consultation are subject to “white-coat persistence” i.e. improved 
persistence before a scheduled visit to the clinic or laboratory.   Consequently, 
databases offer unique opportunities with their large samples of patients with 
hypertension, followed over long time with minimal risk for bias.  
There are many advantages of using databases in observational research on 
medication use.113 One feature is the possibility to study rare events, since they 
contain a lot of information. Another advantage is their data on routine clinical care, 
which makes it possible to study the drugs effectiveness in real practice, and also 
the utilization of the prescribed pharmacological treatment.  Further, they are 
relatively inexpensive and mostly accessible without long delays.113 Data collected 
from medical records contain complete populations representative for routine care, 
thus minimizing the risk for selection bias. Furthermore, they may provide the 
 32 
opportunity of linking prescribing data to clinical parameters, such as diagnosis, vital 
signs, laboratory data and more or less structured clinical notes. However, there are 
some important limitations of using medical records in observational research. 
Diagnoses may be missing or inaccurate, and the validity may vary substantially 
between different primary healthcare centers. While many validation studies have 
been conducted on hospital based diagnoses in the Swedish National Patient 
Register106, validation studies from primary care are to a large extent missing. In 
our studies, inappropriate diagnostic information on hypertension and the included 
comorbidities could potentially lead to selection or information bias. 
MEASURE OF PERSISTENCE 
There are several methodological challenges in assessing persistence with register 
based data.22,70,84,114 We performed sensitivity analyzes and found that persistence 
increased from 65% to 83% when we changed the allowed gap defining 
discontinuation from 15 to 120 days. Similar variations have also been found in other 
studies.115 However, changing the gap did not influence the major determinants of 
discontinuation.  
Although persistence is best calculated from the national prescription databases on 
dispensed drugs, compare to the self-assessment of persistence, the methods have 
to be adapted to the context in each country. There is also a potential bias of non-
responders, and recall bias related to survey. In addition, it is possible that attitudes 
in the patients responding to the questionnaire are different to those not responding. 
Furthermore, all instruments to assess attitudes have their inherent limitations, , IPQ 
and BMQ have previously been used in studies on adherence to antihypertensive 
medication but, to the best of our knowledge, have not previously been used early 
after medication initiation to assess differences in attitudes in patient discontinuing 
treatment, compared to those being persistent. 
STATISTICAL METHODS 
Pharmacoepidemiological studies are generally subject to three sources of bias; 
information bias, selection bias and confounding. A particular problem in 
pharmacoepidemiological studies is the potential for confounding, i.e. a systematic 
error resulting from the fact that a secondary variable is linked to both the exposure 
and the event of interest. Such a confounder could have been an important factor 
associated with non-persistence, potentially taken into account when prescribing. 
Potential factors influencing the decision to prescribe, thus potentially leading to 
confounding, may vary by physician and over time and involve a mix of clinical, 
functional and behavioral patient characteristics.116 Channeling of prescribing to 
specific patients may also occur as a result of guidelines or reimbursement 
restrictions favoring certain drugs. In the in this theses (Study II-IV), we have 
addressed confounding through the Cox regression, but still, it is possible that there 
may be some residual confounding on factors not included in the model. 
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FINDINGS AND IMPLICATIONS 
EPIDEMIOLOGY AND PATIENTS (STUDY I – IV) 
We estimated that the prevalence of known hypertension in the adult population to 
11% in the southwestern part of Stockholm in 2005-2006. Similar proportions were 
found in two other studies in rural Sweden and Stockholm County, also reporting 
diagnosed patients with hypertension in the health care system.32,34,35  The SBU 
estimated the prevalence of high blood pressure in the adult population to be 27%. 
Thus, the proportion of patients unaware of their elevated blood pressure would 
correspond to around 16% of the population in Sweden, and almost exactly one 
million people of the Swedish adult population in 2006.117 . The prevalence of 
hypertension decreases in high-income countries today, while it increases in low- 
and middle-income countries.1 This result refutes the hypertension paradox, that the 
prevalence of hypertension increases although improvement in the pharmacological 
treatment and other therapies.118 Lifestyle modification, including high salt intake119 
and high body weight120, excessive alcohol intake, low socioeconomic status, 
genetic predisposition or family history, sleep apnea, use of illegal drugs and 
tobacco, increasing age, genetic predisposition, diagnosis of prehypertension, are all 
affecting the risk of developing hypertension.121  All these factors need to be taken 
into account in each individual patient, to reduce the risk of developing hypertension, 
and to keep in mind that untreated hypertension can shorten life expectancy by 
approximately five years.122 
The patients newly initiated on antihypertensive drug treatment in three of the 
studies of this thesis (Study II-IV) had similar patient characteristics, including mean 
age, proportion of women and men and comorbidities as studies conducted in 
primary care populations in other countries.23,86,88 Since these patients were newly 
initiated on therapy, they had a lower mean age and less comorbidities than the 
patients with hypertension and either no antihypertensive drug prescribed, newly 
initiated on treatment or prevalent medication users (Study I).    
BLOOD PRESSURE (STUDY I) 
We found that few had a recorded blood pressure below target of 140/90 mm Hg 
(Study I). There are of course several potential explanations to why, including the 
health care provider organization, organizational issues in primary healthcare and 
insufficient systematic follow up. Physicians may prescribe an inappropriate dosing, 
or inadequate drug combinations and may consider side effects with 
antihypertensive drugs a problem, or that available evidence to treat the very old 
insufficient.  Furthermore, patient adherence or persistence to prescribed therapy 
may be low due to lack of motivation among prescribers or patients. In addition, 
some patients may have resistant or secondary hypertension. We also found that the 
proportion reaching blood pressure targets remained low, independent of the 
number of antihypertensive drugs prescribed (Study I). These results may indicate 
that poor persistence or adherence to drug treatment is an important factor to 
achieve target blood pressure goals. 
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However, these results are not so surprising since the guidelines at that time were 
less rigorous in the enforcement to lower the blood pressures by antihypertensive 
drug treatment. It is merely important to acknowledge the fact that this is one out of 
many reasons to why we today face a great problem with patients developing 
cardiovascular disease.  
Half of the patients had mild elevated blood pressure. Most patients have an 
elevated systolic blood pressure of 140-159 mm Hg and/or diastolic blood pressure 
of  90 to 99 mm Hg.123 Due to the high prevalence of patients with mild hypertension, 
the burden of cardiovascular disease caused by hypertension in the general 
population comes from those with relatively mild hypertension. Up until recently it 
has been unclear whether antihypertensive drug treatment prevents cardiovascular 
events and deaths in patients with mild hypertension, but a recent review reported 
that a blood pressure reduction likely prevents stroke and death in these patients.124 
Thus, it is important to treat these patients with mild hypertension, which is also 
supported by the current guidelines that target blood pressure should be below 
140/90 mm Hg, and even lower targets for high-risk patients. 
ANTIHYPERTENSIVE DRUG TREATMENT (STUDY I - IV) 
All our studies presented data on the proportion of patients with a diagnosis of 
hypertension that were treated with antihypertensives and to what extent the 
different drug classes were used. We analyzed prescribing were patients were 
prevalent on antihypertensive drug treatment (Study I) and filled prescriptions in 
patient newly initiating antihypertensive treatment (Study II-IV).  Study I and Study II-
III  have similar study periods for the inclusion of patients (2005-2007), while Study 
IV was performed almost ten years later (2015-2016). 
We found beta blockers and diuretics to be the most commonly prescribed drugs 
among prevalent medication users, although some included were newly initiated on 
antihypertensive treatment (Study I). In patients newly initiated on antihypertensive 
treatment, the most common filled prescriptions during the mid-2000 were the ACE-
Is, diuretics and beta blockers (Study II-III).  
The finding that a majority of patients were most commonly prescribed beta blockers 
and diuretics (Study I), probably reflected the old guidelines in Sweden prior to the 
time of the study, specifically recommending beta blockers and diuretics as first-line 
choices for elderly patients.  Utilization of antihypertensives can vary between 
countries in prescribing patterns. Suggested factors behind this variation include 
cross-country differences in reimbursement policies, therapeutic traditions, impact of 
opinion leaders, domestic pharmaceutical production, and clinical guidelines. 
However, the patterns of use have changed over the past 20 years, and there has 
been a consistent increase in the use of ACEIs, ARBs and CCBs in all countries. 
In study I, we also analyzed gender differences in drug treatment as well as 
prescribing patterns in different age groups and for patients with different 
cardiovascular comorbidities. This is further discussed in the paper, and gender 
differences is also thoroughly assessed in another study from the SPCCD.56  
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When we assessed only those patients newly initiated on treatment, we found that 
ACE-I were the most commonly prescribed drug treatment, followed by diuretics and 
beta blockers (Study II-III). Thus, there is a difference in initiation of treatment and 
patients prevalent on antihypertensive medication. Doctors and patients not wanting 
to change a drug class that “works”, into another, although guidelines tell differently, 
can explain this phenomenon. It is possible that the new guidelines are implemented 
faster today than ten years ago when the study was conducted. This would be 
explained by the more advanced decision-support systems and computerized 
access to medical records we have today.125 However, although some drug classes 
have shown to be favorable in some patients more than others are, the most 
important for the doctor is to lower the blood pressure itself. 
We found choice of initiated antihypertensive drug treatment changed between 
2006-2007 (Study II-III) and 2015 (Study IV). ACE-I was still the most prescribed, but 
on second and third place came the calcium channel blockers and angiotensin 
receptor blockers, respectively. The diuretics and beta blockers were not common at 
all. This is more in line with the current guidelines of the initiation of drug treatment in 
patients with hypertension, and the findings are also found in other countries. Thus, 
doctors do follow the guidelines, but it might take some time before they are 
implemented. 
THERAPY PERSISTENCE (STUDY II) 
An important finding was that one sixth of all patients only purchased their first 
prescription, one out of four patients discontinued the treatment within the first year, 
and a further one tenth discontinued during the second year of follow-up. This early 
discontinuation is in accordance with findings from other settings, although the 
proportion being classfiied as persistent varies substantially between studies.15,22-
27,126 This large variation between studies is most likely attributable both to the 
patient populations included and to the large variation in methodologies.22,70,84 The 
importance of the method was illustrated in the sensitivity analyses conducted in 
which the proportion persistent varied substantially depending on the allowed gap. 
CLASS PERSISTENCE (STUDY III) 
One fourth of all patients filled one prescription only, and approximately 40% of all 
patients discontinued their initial drug class during the first year. This high proportion 
of patients discontinuing treatment early after initiation confirms findings from other 
studies.14,23,88  
In studies where antihypertensive drug classes were compared with one another, 
diuretics and beta blockers most often have been reported with the lowest class 
persistence23,24,87, whereas ACE-I or ARBs have the highest class persistence. 
Accordingly, our crude results found a lower persistence for ACE-inhibitors than for 
diuretics. More important, however, this difference did not remain after adjustment 
for confounding factors shown to be important for drug class persistence. Thus, we 
found no differences in persistence between diuretics and the other drug classes. 
Our observations thus support recent findings on persistence from Germany also 
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using primary healthcare population data, adjusting for many possible confounders.14 
These results suggest that there are no important differences in persistence between 
the most common antihypertensive drug classes. Prior studies may have been 
biased by not adjusting for important factors associated with persistence to 
antihypertensive drug treatment.   
FACTORS INFLUENCING PERSISTENCE TO TREATMENT (STUDY II – III)  
In the study on therapy persistence (Study II), we found that factors associated with 
low therapy persistence to the drug treatment were male sex, lower age, mild-to-
moderately elevated systolic blood pressure, and birth outside Sweden.  
These factors found to be associated with therapy persistence, were also associated 
with poor class persistence (Study III). Similar patterns were also observed in a 
study from Canada.23   
A broad generalized assumption would be to translate the difference between 
therapy and class persistence into a proportion of patients switching treatment, eg. 
those patients who are not persistent to the class, but to some antihypertensive 
treatment, could be considered switchers. We estimated that 25% were switchers by 
counting the proportion of patients who had switch in the Cox regression analysis 
(Study III) and to 19% by subtracting the proportion of patients who were therapy 
persistent to the proportion of patients who were class persistence (results shown in 
this thesis). These results can considered being quite similar, although the methods 
used for estimating switching is different between the studies. Overall, it seems as 
many patients do switch treatment, which should be considered a better option than 
a final discontinuation of treatment.  
THE PATIENTS’ ATTITUDES TOWARDS HYPERTENSION AND DRUGS (STUDY 
IV) 
We found that persistent and non-persistent medication users have slightly different 
attitudes towards the diagnosis of hypertension, drugs in general and the 
antihypertensive drug treatment prescribed. Persistent medication users believe, 
compare to non-persistent,  that hypertensive disease has fewer consequences to 
their life, that the hypertension is a chronic disease and consider to a greater extent 
that the antihypertensive medication protect from future cardiovascular disease, and 
have a more positive attitude towards medication, in particular for specific 
antihypertensive medications, as compare to non-persistent patients. They are also 
less concerned about the effects of antihypertensive drugs.  
These findings suggest that the health care providers in primary health care, but also 
pharmacists at the pharmacy, should inform the patients about the importance of 
antihypertensive drug treatment, that hypertension is a chronic disease and that 
there are a lot to benefit from antihypertensive drug treatment. 
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CONCLUSIONS 
 
 Only one in four hypertensive patients reach a target blood pressure below 
140/90 mm Hg in the primary health care. During the time of the study, 
patients were mostly prescribed beta blockers and diuretics. Patients not 
reaching target blood pressure may be explained by poor adherence or 
persistence, since the increase in the number of prescribed drugs did not 
correspond to an increased proportion of patients with target blood pressure. 
 
 Major determinants of therapy persistence to antihypertensive drug treatment 
are male sex, young age, mild-to-moderate systolic blood pressure elevation, 
and birth outside of Sweden. 
 
 There appears to be no difference in drug class persistence between diuretics 
and other major antihypertensive drug classes, when factors known to be 
associated with poor persistence are taken into account. 
 
 There are some differences in attitudes towards hypertension diagnosis and 
drugs in overall between persistent and non-persistent patients. Patients 
persistent to drug treatment, compare to non-persistent, believed that their 
diagnosis of hypertension were chronic, and that they need and benefit from 
antihypertensive medication in preventing future cardiovascular disease. 
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FUTURE PERSPECTIVES 
A few questions have arisen during the course of studies of this thesis, including: 
 
 How does the degree of therapy persistence effect the patient’s ability to 
reach target blood pressure? 
 How does the risk of cardiovascular disease and death change depending on 
the patient’s degree of medication persistence and medication adherence, 
given that we have 10-year follow-up of patients in the SPCCD?  
 Have the proportion of medication persistent patients increased in different 
part of the world over the years? A new review with the same method used by 
Cramer et.al.22 from 2008, would provide new knowledge and insight. 
 What is the cost for the society to pay for patients being non-persistent tp 
treatment and compare those figures with cost of adequate monitoring of 
patients after initiation of antihypertensive treatment (lifestyle or medication)? 
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SAMMANFATTNING PÅ SVENSKA 
Hypertoni är en av de främsta orsakerna till förtida sjuklighet och död. I Sverige 
uppskattas omkring 2 miljoner personer av den vuxna befolkningen ha hypertoni 
som kräver medicinsk behandling. Mildare former är ofta symptomfria, men 
obehandlad hypertoni ökar risken att insjukna i kranskärlssjukdom, hjärtsvikt, 
slaganfall, njursvikt och andra hjärt-kärlsjukdomar. Högt blodtryck ökar dessutom 
risken för utveckling av demens. Genom att kombinera olika blodtryckssänkande 
medel går det att nå målblodtryck <140/90 mm Hg hos de flesta personer. 
Undersökningar visar dock att andelen som når behandlingsmålet sällan uppgår till 
mer än 20–30 % av dem som ordinerats blodtryckssänkande läkemedel. En viktig 
bidragande faktor tros vara bristande långtidsföljsamhet till behandlingen, då många 
studier visar på att patienterna avslutar behandlingen redan inom ett år efter 
behandlingsstart.  
Vi började med att kartlägga läkemedelsbehandlingen och måluppfyllelse av 
blodtryck hos patienter med högt blodtryck. I studien tog vi med 24 vårdcentraler från 
sydvästra Stockholm med totalt 21 167 patienter som besökt någon av de 
inkluderade vårdcentralerna under 2005-2006. Vi fann att endast en utav fyra 
patienter når målblodtryck under 140/90 mm Hg.  
Nästa steg var att studera persistens till blodtryckssänkande läkemedel och vilka 
faktorer som är kopplade till att patienterna fortsätter ta sina läkemedel. Vi använde 
oss av hypertonipatienters elektroniska journaler från de 48 vårdcentralerna som var 
med i studien. Vi sammankopplade data från nationella register med 
läkemedelsuthämtningar, diagnoser från sjukhus, död, födelseland, inkomst och 
utbildningsnivå. Vi fann 5225 patienter som var nyinsatta på blodtryckssänkande 
behandling under 2006- 2007. Över en tredjedel av patienterna slutade helt att ta 
blodtryckssänkande behandling inom två års tid. Vi fann att de faktorer som verkar 
vara sammankopplade med en sämre långtidsföljsamhet till blodtryckssänkande 
behandling är manligt kön, ung ålder, mild till måttlig systoliskt blodtryckshöjning och 
födelseland utanför Sverige. 
En fråga kvarstod från den tidigare studien, och det var att se om 
långtidsföljsamheten skiljer sig åt mellan de olika blodtryckssänkande 
läkemedelsklasserna? Vi använde liknande metod som beskrivits i studien ovan, 
men analyserade specifikt varje läkemedelsklass. Vi fann att det inte var några 
skillnader i långtidsföljsamhet till de olika läkemedelsklasserna i jämförelse med 
vätskedrivande läkemedelsbehandling. 
Även om registerstudier är viktiga och kan ge mycket värdefull information, så kan 
de inte ge all information. De saknar information om patienters åsikter och attityder. 
För att utöka kunskaperna om långtidsföljsamhet till blodtryckssänkande behandling, 
bestämde vi oss för att studera patienternas attityder till högt blodtryck och 
läkemedelsbehandling, och se om det finns skillnader mellan en som är 
långtidsföljsam och en som inte är det. Vi skickade ut enkäter till patienter som var 
nyinsatta på blodtryckssänkande behandling och fann genom analys av 
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läkemedelsuttag från Läkemedelsregistret att 609 (86%) var långtidsföljsamma och 
102 (14%) icke-långtidsföljsamma till den blodtryckssänkande behandlingen. Vi fann 
att i jämförelse med icke-långtidsföljsamma så uppfattade långtidsföljsamma 
patienter i högre grad att hypertonidiagnosen var kronisk De uppfattade att den hade 
mindre konsekvenser för deras liv och att de kan förhindra hjärt-kärlsjukdom genom 
att ta blodtryckssänkande behandling samt att det är positivt med 
läkemedelsbehandling vid sjukdom.  
Studierna syftade till att identifiera orsaker till bristande behandlingseffekter vid 
hypertoni och studera hur behandlingen kan förbättrats. Att skapa förståelse kring 
varför så få patienter når sitt målblodtryck och identifiera lösningar som kan förbättra 
deras behandling. Detta kan bidra till kampen för att minska risken för följdsjukdomar 
och för tidig död hos patienter med hypertoni. 
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